diuretics + human albumin

A therapeutic combination regimen consisting of long-term intravenous human albumin administration alongside standard medical treatment (SMT) with diuretics, specifically evaluated in the ANSWER trial led by the University of Bologna. The regimen involves the administration of 40 g of human albumin twice weekly for two weeks, followed by 40 g weekly for up to 18 months, in addition to a diuretic regimen typically comprising an anti-aldosteronic drug (e.g., spironolactone at ≥200 mg/day) and a loop diuretic (e.g., furosemide at ≥25 mg/day). This combination is designed for patients with decompensated liver cirrhosis and uncomplicated ascites to improve oncotic pressure, reduce systemic inflammation, and manage fluid retention, ultimately aiming to improve survival and reduce complications like refractory ascites and spontaneous bacterial peritonitis.

Other names

long-term human albumin plus standard medical treatmentlong-term human albumin administration plus standard medical treatment